Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 6301 - 6325 of 6869 in total

Ozagrel

Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes.
Investigational

SCH-486757

Sch 486757 has been used in trials studying the treatment of Cough.
Investigational

GSK-1004723

Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.
Investigational

Celastrol

Celastrol is a pentacyclic triterpenoid isolated from the root extracts of Tripterygium wilfordii.
Investigational

Tryptophanyl-5'amp

Experimental

Plevitrexed

Investigational

Etoposide toniribate

Investigational

9-benzyl-2,3,4,9-tetrahydro-1H-carbazole-8-carboxylic acid

Experimental

3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester

Experimental

2-[4-(4-Chlorophenyl)Cyclohexylidene]-3,4-Dihydroxy-1(2h)-Naphthalenone

Experimental

(5Z)-3-(4-CHLOROPHENYL)-4-HYDROXY-5-(1-NAPHTHYLMETHYLENE)FURAN-2(5H)-ONE

Experimental

6-{4-[HYDROXY-(4-NITRO-PHENOXY)-PHOSPHORYL]-BUTYRYLAMINO}-HEXANOIC ACID

Experimental

4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE

Experimental

Alrestatin

Experimental

2-Chlorodideoxyadenosine

Experimental

5-(6-Amino-9h-Purin-9-Yl)-4-Hydroxytetrahydrofuran-3-Yl Dihydrogen Phosphate

Experimental

9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine

Experimental

Genz-10850

Experimental

Gavestinel

Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.
Investigational

Hydroxy(oxo)(2-{(1S)-2,2,2-trifluoro-1-[2-(trimethylarsonio)ethoxy]ethyl}phenyl)ammonium

Experimental

8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM

Experimental

Volixibat

Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH. Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational

(6S)-5,6,7,8-tetrahydrofolic acid

Experimental

RU90395

Experimental

6-hydroxy-FAD

Experimental
Displaying drugs 6301 - 6325 of 6869 in total